92 related articles for article (PubMed ID: 20668444)
1. Clinically significant CYP2C inhibition by noscapine but not by glucosamine.
Rosenborg S; Stenberg M; Otto S; Ostervall J; Masquelier M; Yue QY; Bertilsson L; Eliasson E
Clin Pharmacol Ther; 2010 Sep; 88(3):343-6. PubMed ID: 20668444
[TBL] [Abstract][Full Text] [Related]
2. Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction.
Fang ZZ; Zhang YY; Ge GB; Huo H; Liang SC; Yang L
Br J Clin Pharmacol; 2010 Feb; 69(2):193-9. PubMed ID: 20233183
[TBL] [Abstract][Full Text] [Related]
3. Characterization of inhibition kinetics of (S)-warfarin hydroxylation by noscapine: implications in warfarin therapy.
Zhang N; Seguin RP; Kunze KL; Zhang YY; Jeong H
Drug Metab Dispos; 2013 Dec; 41(12):2114-23. PubMed ID: 24046330
[TBL] [Abstract][Full Text] [Related]
4. Impact of visceral leishmaniasis and curative chemotherapy on cytochrome P450 activity in Brazilian patients.
Lanchote VL; Almeida R; Barral A; Barral-Netto M; Marques MP; Moraes NV; da Silva AM; Souza TM; Suarez-Kurtz G
Br J Clin Pharmacol; 2015 Nov; 80(5):1160-8. PubMed ID: 25940755
[TBL] [Abstract][Full Text] [Related]
5. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole.
Uno T; Sugimoto K; Sugawara K; Tateishi T
Ther Drug Monit; 2008 Jun; 30(3):276-81. PubMed ID: 18520598
[TBL] [Abstract][Full Text] [Related]
6. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients.
Boruban MC; Yasar U; Babaoglu MO; Sencan O; Bozkurt A
J Chemother; 2006 Aug; 18(4):421-4. PubMed ID: 17024799
[TBL] [Abstract][Full Text] [Related]
8. Effects of Angelicae tenuissima radix, Angelicae dahuricae radix and Scutellariae radix extracts on cytochrome P450 activities in healthy volunteers.
Yi S; Cho JY; Lim KS; Kim KP; Kim J; Kim BH; Hong JH; Jang IJ; Shin SG; Yu KS
Basic Clin Pharmacol Toxicol; 2009 Oct; 105(4):249-56. PubMed ID: 19422358
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.
Takahashi H; Kashima T; Nomizo Y; Muramoto N; Shimizu T; Nasu K; Kubota T; Kimura S; Echizen H
Clin Pharmacol Ther; 1998 May; 63(5):519-28. PubMed ID: 9630825
[TBL] [Abstract][Full Text] [Related]
10. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
[TBL] [Abstract][Full Text] [Related]
11. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".
Chainuvati S; Nafziger AN; Leeder JS; Gaedigk A; Kearns GL; Sellers E; Zhang Y; Kashuba AD; Rowland E; Bertino JS
Clin Pharmacol Ther; 2003 Nov; 74(5):437-47. PubMed ID: 14586384
[TBL] [Abstract][Full Text] [Related]
12. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.
Obayashi K; Nakamura K; Kawana J; Ogata H; Hanada K; Kurabayashi M; Hasegawa A; Yamamoto K; Horiuchi R
Clin Pharmacol Ther; 2006 Aug; 80(2):169-78. PubMed ID: 16890578
[TBL] [Abstract][Full Text] [Related]
13. Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo.
Ryu JY; Song IS; Sunwoo YE; Shon JH; Liu KH; Cha IJ; Shin JG
Clin Pharmacol Ther; 2007 Nov; 82(5):531-40. PubMed ID: 17392720
[TBL] [Abstract][Full Text] [Related]
14. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
[TBL] [Abstract][Full Text] [Related]
15. Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19.
Rost KL; Roots I
Hepatology; 1996 Jun; 23(6):1491-7. PubMed ID: 8675169
[TBL] [Abstract][Full Text] [Related]
16. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes.
Karam WG; Goldstein JA; Lasker JM; Ghanayem BI
Drug Metab Dispos; 1996 Oct; 24(10):1081-7. PubMed ID: 8894508
[TBL] [Abstract][Full Text] [Related]
17. Interaction of OTC drug noscapine and acenocoumarol and phenprocoumon.
Lokhorst B; Rolfes L; Jessurun NT
Br J Clin Pharmacol; 2019 May; 85(5):1041-1043. PubMed ID: 30809820
[No Abstract] [Full Text] [Related]
18. Effects of myricetin, an antioxidant, on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats: possible role of cytochrome P450 3A4, cytochrome P450 2C9 and P-glycoprotein inhibition by myricetin.
Choi DH; Li C; Choi JS
J Pharm Pharmacol; 2010 Jul; 62(7):908-14. PubMed ID: 20636879
[TBL] [Abstract][Full Text] [Related]
19. Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms.
Chen BL; Chen Y; Tu JH; Li YL; Zhang W; Li Q; Fan L; Tan ZR; Hu DL; Wang D; Wang LS; Ouyang DS; Zhou HH
J Clin Pharmacol; 2009 May; 49(5):574-81. PubMed ID: 19398604
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients.
Gunes A; Bilir E; Zengil H; Babaoglu MO; Bozkurt A; Yasar U
Basic Clin Pharmacol Toxicol; 2007 Jun; 100(6):383-6. PubMed ID: 17516991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
